Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 25, 2010

View Archived Issues

First-in-human data presented on GPVI-Fc fusion protein revacept

INCB-028050 therapy leads to clinical response in phase II trial in active RA

New monoglyceride lipase inhibitors identified at Janssen

ADRB2 gene polymorphisms may predict response to timolol and betaxolol therapy in glaucoma

Phase II data show eculizumab to be effective in atypical hemolytic uremic syndrome

New serotonin 5-HT6 receptor ligands described by Abbott

Michael J. Fox Foundation awards grant to XenoPort for Parkinson's disease research

GSK to sell U.S. penicillin facility and products to Dr. Reddy's

FDA clears BG Medicine's Galectin-3 test for heart failure

Provectus updates compassionate use program for anticancer candidate PV-10

New allosteric modulator of metabotropic glutamate mGlu2 receptor has procognitive effects in vivo

In vivo antitumor effects of BIIB-024 support evaluation in phase I trials in melanoma/solid tumors

RADAR trial supports use of REG1 anticoagulation system in patients with acute coronary syndrome

Roche claims new inhibitors of Mdm2-p53 interaction

Novel tyrosine-protein kinase BTK inhibitors presented

Glycotex receives grant to develop GLYC-101 gel for wound healing

Boehringer Ingelheim patents novel PI3K inhibitors

Tragara advances multikinase inhibitor SB-1317 to phase I trial

Advaxis begins ADX11-001 trial in cervical cancer

Advanced Proteome Therapeutics enters agreement to advance its SLMT platform

Locus Pharma divulges new inhibitors of tyrosine-protein kinase BTK

Idenix receives milestone for GSK-2248761 trial in HIV

Grifols secures financing for acquisition of Talecris Biotherapeutics

GlaxoSmithKline reviews Q3 achievements

Mologen's colorectal cancer candidate MGN-1703 cleared for phase II/III study

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 13, 2026.
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
Keros reports beneficial effects of RKER-065 in ALS model
BioWorld Science
Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
HX-16108 holds promise for treating inflammatory skin diseases
BioWorld Science
Atopic dermatitis (AD) is an inflammatory skin disease accompanied by pruritus, for which IL-13 and IL-31 are clinically validated targets. Earendil Labs Inc. has...